876-P: Effectiveness and Tolerability of Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily In Patients with Type 2 Diabetes in Real Life—The INTENSIFY Study

There is a paucity of data evaluating the strategy of intensification of canagliflozin therapy by increasing the dose from canagliflozin 100 mg/d (CANA100) to canagliflozin 300 mg/d (CANA300), since all clinical trials compared both doses separately. The aim of this multicentric study was to assess in real life the effectiveness and tolerability of the intensification of canagliflozin to 300 mg/d in patients with T2DM and suboptimal metabolic control with CANA100. The primary outcome variables were changes in A1c and weight at the end of the follow-up. 317 patients met the inclusion criteria (age 62.2 years, A1c 7.55%, weight 88.6 kg). Median time of treatment with CANA300 was 20.8 months. Switching to CANA300 induced a significant decrease in A1c (-0.47%) and weight (-2.9 kg), both p